Show simple item record

dc.contributor.authorBoettler, Tobias
dc.contributor.authorNewsome, Philip N
dc.contributor.authorMondelli, Mario U
dc.contributor.authorMaticic, Mojca
dc.contributor.authorCordero, Elisa
dc.contributor.authorCornberg, Markus
dc.contributor.authorBerg, Thomas
dc.date.accessioned2021-06-16T13:18:09Z
dc.date.available2021-06-16T13:18:09Z
dc.date.issued2020-04-02
dc.identifier.citationJHEP Rep. 2020 Jun;2(3):100113. doi: 10.1016/j.jhepr.2020.100113. Epub 2020 Apr 2.en_US
dc.identifier.pmid32289115
dc.identifier.doi10.1016/j.jhepr.2020.100113
dc.identifier.urihttp://hdl.handle.net/10033/622906
dc.description.abstractThe coronavirus disease 2019 (COVID-19) pandemic poses an enormous challenge to healthcare systems in affected communities. Older patients and those with pre-existing medical conditions have been identified as populations at risk of a severe disease course. It remains unclear at this point to what extent chronic liver diseases should be considered as risk factors, due to a shortage of appropriate studies. However, patients with advanced liver disease and those after liver transplantation represent vulnerable patient cohorts with an increased risk of infection and/or a severe course of COVID-19. In addition, the current pandemic requires unusual allocation of healthcare resources which may negatively impact the care of patients with chronic liver disease that continue to require medical attention. Thus, the challenge hepatologists are facing is to promote telemedicine in the outpatient setting, prioritise outpatient contacts, avoid nosocomial dissemination of the virus to patients and healthcare providers, and at the same time maintain standard care for patients who require immediate medical attention.en_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectACE-I, angiotensin-converting enzyme inhibitoren_US
dc.subjectACE2, angiotensin-converting enzyme 2en_US
dc.subjectACLF, acute-on-chronic liver failureen_US
dc.subjectALT, alanine aminotransferaseen_US
dc.subjectAST, aspartate aminotransferaseen_US
dc.subjectCOVID-19, coronavirus disease 2019en_US
dc.subjectEGD, esophagogastroduodenoscopyen_US
dc.subjectERC, endoscopic retrograde cholangiographyen_US
dc.subjectHCC, hepatocellular carcinomaen_US
dc.subjectMELD, model for end-stage liver diseaseen_US
dc.subjectNAFLD, non-alcoholic fatty liver diseaseen_US
dc.subjectNASH, non-alcoholic steatohepatitisen_US
dc.subjectNUC, nucleoside analogueen_US
dc.subjectPIs, protease inhibitorsen_US
dc.subjectRdRp, RNA-dependent RNA polymeraseen_US
dc.subjectSARS-CoV-2, severe acute respiratory syndrome coronavirus 2en_US
dc.subjectULN, upper limit of normalen_US
dc.titleCare of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper.en_US
dc.typeReviewen_US
dc.identifier.eissn2589-5559
dc.contributor.departmentCiiM, Zentrum für individualisierte Infektionsmedizin, Feodor-Lynen-Str.7, 30625 Hannover.en_US
dc.identifier.journalJHEP reports : innovation in hepatologyen_US
dc.source.volume2
dc.source.issue3
dc.source.beginpage100113
dc.source.endpage
refterms.dateFOA2021-06-16T13:18:10Z
dc.source.journaltitleJHEP reports : innovation in hepatology
dc.source.countryNetherlands


Files in this item

Thumbnail
Name:
Publisher version
Thumbnail
Name:
Boettler et al.pdf
Size:
587.7Kb
Format:
PDF
Description:
Open Access publication

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 International
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International